Skip to main content

HeartBeam (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio

Tipranks - Tipranks - Thu Mar 5, 10:30AM CST

Austin, Texas, United States, March 4th, 2026, FinanceWire

Claim 70% Off TipRanks Premium

HeartBeam (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio(TM), a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam’s first commercial customer and plans to make an investment in the company, underscoring strategic alignment. The staged rollout will integrate HeartBeam’s synthesized 12-lead ECG technology into ClearCardio’s cardiac prevention program for arrhythmia assessment, enabling patients to capture clinical-grade ECG readings from home using HeartBeam’s patented cable-free 3D ECG system. Structured as a Letter of Intent outlining subscription-based commercial terms and a collaborative deployment plan, the agreement supports HeartBeam’s broader growth strategy, including expansion into concierge care and preventive cardiology networks, continued development of its 12-lead ECG patch monitor and advancement of its AI-driven cardiac care initiatives.

To view the full press release, visit https://ibn.fm/EDyjd

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement. 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Contact

IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com

If you want to submit your press release through TipRanks NewsWire, please go to the following link.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).